| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10213027 | Atherosclerosis | 2018 | 25 Pages |
Abstract
These differences do not hinder the use of female mice when AAV8-PCSK9 doses are taken into consideration. However, localization to and production of AAV8-PCSK9 in organs besides the liver in mice may introduce confounding factors into studies and should be considered during experimental design.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Aimee E. Vozenilek, Cassidy M.R. Blackburn, Robert M. Schilke, Sunitha Chandran, Reneau Castore, Ronald L. Klein, Matthew D. Woolard,